Altace Patent Suit Cited By Icahn In Latest Missive Against Mylan/King Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor maintains that Cobalt Pharmaceuticals' patent challenge could mean a generic version of the ACE inhibitor will be launched in mid-2005. Mylan suggests that Icahn's opposition is motivated in part by desire to cash-in on short position in King.